Semaphorin 3A Controls Allergic and Inflammatory Responses in Experimental Allergic Conjunctivitis by 田中 純美
 学位論文の要約 
 
Semaphorin 3A Controls Allergic and Inflammatory 
Responses in Experimental Allergic Conjunctivitis 
（セマフォリン 3Aを用いたアレルギー性結膜炎に対する生物製
剤治療法の開発） 
 
 
 
 
  
   
 
Junmi Tanaka 
田中 純美 
 
Department of Ophthalmology and Visual Science 
Yokohama City University Graduate School of Medicine 
    横浜市立大学 大学院医学研究科 医科学専攻視覚器病態学 
 
（ Doctoral Supervisor：Nobuhisa Mizuki, Professor ） 
（ 指導教員：水木信久 教授 ）
1 
 
学位論文の要約 
 
Semaphorin 3A Controls Allergic and Inflammatory 
Responses in Experimental Allergic Conjunctivitis 
（セマフォリン 3Aを用いたアレルギー性結膜炎に対する生物製
剤治療法の開発） 
 
 
1. INTRODUCTION 
Allergy has been called “the 21st century disease”. In Japan the prevalence of allergic 
conjunctival diseases is estimated to be as high as 15%–20% of the population and is on 
the rise (Takamura et al., 2011). Currently, therapies for ocular allergy have evolved to a 
point where there are now highly efficacious treatments for most of patients. Despite 
this, those with the most severe, chronic allergic conjunctivitis still experience 
substantial disease symptomatology. These patients represent up to 30% of all allergic 
conjunctivitis sufferers, and thus constitute a significant unmet need (Uchio, 2008). 
Recent studies, the role of Semaphorin-3A (SEMA3A) in the immune system has been 
revealed partially. (i)Enhances DC (dendritic cells) migration into lymph nodes, (ii) 
Induces apoptosis in M-CSF (macrophage colony-stimulating factor)-derived 
macrophages, and (iii) Terminates the immune response (Lepelletier et al., 2007; 
Moretti et al., 2008; Ji et al., 2009; Schlahsa et al., 2014). SEMA3A is widely accepted by 
the concept of "immune semaphorin" (Kikutani and Kumanogoh, 2003). In this study, 
we investigated the therapeutic potential of SEMA3A in experimental allergic 
conjunctivitis (EAC) mice model. 
 
2. MATERIALS AND METHODS 
BALB/c mice were intraperitoneally sensitized (50μg on day 0, 5 and day 10) to short 
ragweed pollen (SRW) followed by repeated SRW eye drops challenges (2μg from day 11). 
Different concentrations of SEMA3A (10 U, 100 U, 1000 U) and PBS were adopted as a 
therapeutic agent or as control. Actively immunized mice were treated with the agent 
just before or at the same time as the eye drop challenges. Ophthalmic group were 
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challenged via eye drops with the dosage of 10μL per eye twice a day for 4 weeks. Mice 
were evaluated using Haematoxylin and eosin staining, Immunofluorescence and light 
microscope photographs. For comparison, five types of commercial ophthalmic 
formulations for allergy were quantified using clinical characteristics. 
 
3. RESULTS 
SEMA3A as a biological agent, showed the beneficial activity in ocular allergic 
processes and the less damage to the intraocular tissue. Clinical score of composite 
ocular symptoms of the mice treated with SEMA3A were significantly decreased both in 
the immediate phase and the late phase compared to those treated with commercial 
ophthalmic formulations and non-treatment mice. SEMA3A treatment attenuates 
infiltration of eosinophils into conjunctiva in EAC Mice. The score of eosinophil 
infiltration in the conjunctiva of SEMA3A1000U-treated group were significantly lower 
than low-concentration of SEMA3A treated groups and non-treated group. SEMA3A 
treatment also suppressed T-cell proliferation in vitro and decreased serum total IgE 
levels in EAC mice. Moreover, Treatment of Sema3A suppressed Th2-related cytokines 
(IL-5, IL-13 and IL-4) and pro-inflammatory cytokines (IFN-γ, IL-17 and TNF-α) release, 
but increased regulatory cytokine IL-10 concentration in the conjunctiva of EAC mice. 
 
4. DISCUSSION 
Eosinophils have been studied extensively in relation to priming, and are thought to 
be key players in the late phase and in chronic allergic conditions (Godthelp et al., 1996). 
This eosinophilic priming translates clinically to more severe allergic responses (Yuki et 
al., 2011). The suppression of eosinophil migration is a key in the treatment of allergic 
conjunctivitis. 
Nrp-1, which was originally identified as a cell surface glycoprotein, functions as a 
SEMA3A receptor (Kolodkin et al., 1997). Nrp-1 has been identified as a specific marker 
for CD4+CD25+ regulatory T cells (Tregs) (Bruder et al., 2004). Recently, one report has 
suggested that Nrp-1 in Tregs contributes to prolonged contact between Tregs and DCs, 
which inhibits T cell activation at steady state (Sarris et al., 2008). Furthermore, 
Nrp-1+ Tregs preferentially produce IL-10 upon SEMA3A stimulation (Catalano, 2010).  
the secretion of SEMA3A by activated T cells during the immune response is delayed, 
suggesting that sema3A/Np-1 interactions participate in terminating the immune 
response, thus restraining overactivation. In fact, Regardless of the suppressive 
function that SEMA3A exerts in adaptive immune responses (Wen et al., 2010). As 
described above and the findings in this study suggest that SEMA3A in Tregs exerts 
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suppressive functions, presumably by mediating Treg stop signals on DCs and by 
producing regulatory cytokines 
 
Due to the insufficiency of the non-steroid eye drops, topical steroids are still being 
used in the treatment of serious allergic conjunctivitis cases because of their strong 
effects (Sherif and Pleyer, 2002). However, the long term continuous usage of the topical 
steroids results in corneal epithelial disorder refractory. Other side effects include 
increased intraocular pressure, secondary glaucoma and secondary cataract. 
To overcome the risks described above, for the first time our study demonstrated the 
therapeutic potential of SEMA3A for AC. SEMA3A as a biological agent, showed the 
beneficial activity in ocular allergic processes with less damage to the intraocular 
tissues. SEMA3A provides a new intervention strategy and potential therapy for ocular 
allergy; and could reduce or eliminate the usage of topical steroid. SEMA3A may be 
valuable presence as a therapeutic agent for allergic diseases. 
In conclusion, the new treatment our group developed kept the protective functions of 
the immune system intact and responded to the acute and chronic perturbations of 
Figure 1 
SEMA3A and its receptors 
(neuropilin-1 (NP-1), plexin 
A1-A4),  play versatile roles in 
angiogenesis, axon guidance, cell 
survival, migration, and invasion.  
Recently, several roles of SEMA3A 
in the immune system have 
emerged.   SEMA3A and its 
receptors are expressed in a variety 
of lymphoid and myeloid cells and 
affect immune cell functions, 
including cell proliferation, 
differentiation, chemotaxis, and 
cytokine production. 
 
Kigel B et al. (2011). Blood. 118; 
15:4285-96.  
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ocular allergy in the meantime. 
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Figure 2.  
SEMA3A showed tissue penetration and the effect of maintaining the barrier 
function of the conjunctival epithelium by administration of high concentrations. 
Sections were stained with antibodies against SMA3A (green), fluorescent Alexa 
Fluor 546 phalloidin (red) for actin, and 4′6′ -diamidino-2-phenylondole 
dihydrochloride (DAPI) (blue) was used to label cell nuclei. SEMA3A 1000U 
instillation mice (Right) compared with the non-treatment mice (Left). Scale 
Bar=50um. 
SEMA3A showed a clear therapeutic effect on day-4. SEMA3A treated mice 
showed the inhibitory effect of allergic cellular reaction, such as conjunctival 
epithelial cell arrangement disturbance and dropout; goblet cell expanding and 
increasing, compared with the non-treatment mice. 
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